Holen Sie sich die Stockscreener-App
106.82
9.90%
9.62
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
Will Nuvalent’s Momentum Continue? - StocksToTrade
Nuvalent CSO Pelish sells shares worth $501,752 By Investing.com - Investing.com Nigeria
Nuvalent CSO Pelish sells shares worth $501,752 - Investing.com India
Nuvalent (NUVL) chief legal officer Miller sells $676k in stock - Investing.com Australia
Nuvalent (NUVL) chief development officer sells $721k in stock By Investing.com - Investing.com UK
Nuvalent (NUVL) chief development officer sells $721k in stock - Investing.com
Nuvalent initiated with a Buy at Canaccord - MSN
Aug Spikes: Will Nuvalent Inc stock outperform tech sector in 2025July 2025 Drop Watch & Expert Curated Trade Ideas - moha.gov.vn
Nuvalent's Chief Legal Officer Sells 10,000 Shares - TradingView — Track All Markets
Nuvalent, Inc. Reports Q3 2025 Progress and Financials - MSN
Avoiding Lag: Real-Time Signals in (NUVL) Movement - Stock Traders Daily
Bear Alert: How Nuvalent Inc stock performs in weak economyWeekly Stock Analysis & Daily Profit Maximizing Tips - moha.gov.vn
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Nuvalent Earnings Notes - Trefis
What's Going On With Royalty Pharma Stock Wednesday? - Benzinga
PRN_FinancialWrapper | PR NewswireNuvalent, Inc.Class A Common Stock (Nasdaq:NUVL) Stock Quote - FinancialContent
Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500
Nuvalent’s royalty interest acquired by Royalty Pharma - MSN
3 Biotech Stocks With Major 2026 Catalysts - Nasdaq
Truist Securities Initiates Coverage of Nuvalent (NUVL) with Buy Recommendation - MSN
Nuvalent (NUVL): Assessing an Expensive-Looking Valuation After a Strong Multi-Year Share Price Run - Yahoo Finance
Nuvalent, Inc. $NUVL Shares Bought by Voya Investment Management LLC - MarketBeat
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Nuvalent files for mixed shelf offering size not disclosedSEC filing - marketscreener.com
Technical Reactions to NUVL Trends in Macro Strategies - Stock Traders Daily
What drives Nuvalent Inc stock priceStock Buyback Updates & Follow Top Performers in the Community - earlytimes.in
Why Nuvalent Inc. stock remains a top recommendationJuly 2025 WrapUp & High Accuracy Swing Trade Signals - Улправда
Can Nuvalent Inc. stock reach $100 price target2025 Big Picture & Proven Capital Preservation Methods - Улправда
JPMorgan Chase & Co. Lowers Nuvalent (NASDAQ:NUVL) Price Target to $145.00 - MarketBeat
Aug Sentiment: Is Nuvalent Inc. stock a defensive play in 2025Weekly Loss Report & Community Trade Idea Sharing Platform - DonanımHaber
Is Nuvalent Inc. stock a defensive play in 20252025 Key Lessons & Daily Stock Momentum Reports - DonanımHaber
JP Morgan Lowers Target Price for Nuvalent (NUVL) to $145 | NUVL Stock News - GuruFocus
Certain Restricted Stock Units of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2025. - marketscreener.com
Certain Options of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2025. - marketscreener.com
66,836,884 Common Stock of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2025. - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN) - The Globe and Mail
Barclays Reaffirms Their Buy Rating on Nuvalent (NUVL) - The Globe and Mail
UBS reiterates Buy rating on Nuvalent stock, citing Royalty Pharma deal - Investing.com Canada
[8-K] Nuvalent, Inc. Reports Material Event | NUVL SEC FilingForm 8-K - Stock Titan
Nuvalent’s Royalty Interest Acquired by Royalty Pharma - The Globe and Mail
Nuvalent Acknowledges Royalty Pharma's Acquisition of Royalty Interest - TradingView — Track All Markets
Royalty Pharma Acquires Royalty Interest in Nuvalent's Potential Lung Cancer Therapies - marketscreener.com
Royalty Pharma acquires royalty interest in Nuvalent's neladalkib and zidesamtinib for up to $315 million - marketscreener.com
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million - Quiver Quantitative
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million - marketscreener.com
Royalty Pharma (Nasdaq: RPRX) buys Nuvalent NSCLC royalties for up to $315M - Stock Titan
Nuvalent announces public offering of common stock - MSN
Nuvalent, Inc. $NUVL Shares Acquired by Braidwell LP - MarketBeat
Is Nuvalent Inc stock a defensive play in 2025Trade Analysis Summary & Expert Curated Trade Setup Alerts - moha.gov.vn
Natixis Makes New $1.75 Million Investment in Nuvalent, Inc. $NUVL - MarketBeat
Insider Selling: Nuvalent (NASDAQ:NUVL) CFO Sells 7,084 Shares of Stock - MarketBeat
Nuvalent (NUVL) director discloses RSU and stock option acquisitions - Stock Titan
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):